The patients enrolled in this study were selected according to the following criteria: (1) autopsy cases with histologically confirmed metastatic primary lung cancer, (2) death caused by cancer progression, (3) cfDNA extracted from stored plasma samples collected within the 3-month period before death, and (4) written informed consent obtained from the patient during her or his lifetime of the protocol approved by the institutional review board of Kanazawa University Graduate School of Medicine (approval # 327). The protocol for the NGS-based genotyping assays used in tumor tissues and cfDNA from patients with advanced NSCLC applied to specimens obtained at autopsy. We collected the following clinical data: sex, smoking history, diagnosis date, histological type, treatment regimen for lung cancer and ages at diagnosis and death. The study was conducted in accordance with the provisions of the Declaration of Helsinki.
Copyright and License information: The Author(s) ©2021
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Note: The content above has been extracted from a research article, so it may not display correctly.